Company: CGCT
Filing Date: 2025-03-05
Form Type: S-1/A
Source: 0001104659-25-020969
Chunk: 348

Company: Cartesian Growth Corp III
Filing Date: 2025-03-05
Form: S-1/A
Chunk 348
---
 as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the
balance sheets as current or non-current based on whether or not net cash settlement or conversion of the instrument could be required
within 12 months of the balance sheet date. The underwriters’ over-allotment option is deemed to be a freestanding financial
instrument indexed on the contingently redeemable shares and will be accounted for as a liability pursuant to ASC 480 if not fully
exercised at the time of the Proposed Public Offering.

Warrant Instruments

The Company will account for the public warrants
and Private Placement Warrants to be issued in connection with the Proposed Public Offering and the private placement in accordance with
the guidance contained in FASB ASC Topic 815, “Derivatives and Hedging”. Accordingly, the Company evaluated and will
classify the warrant instruments under equity treatment at their assigned values. There are no public warrants or Private Placement Warrants
currently outstanding as of December 31, 2024.

Recent Accounting Pronouncements

Management does not believe that any recently
issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial
statements.

<div align='center'>F-10

Cartesian Growth Corporation IIINOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 2024</div>

Note 3 — Proposed Public Offering

In the Proposed Public Offering, the Company
will offer for sale up to 20,000,000 Units (or 23,000,000 Units if the underwriters’ over-allotment option is exercised
in full) at a purchase price of $10.00 per Unit. Each Unit consists of one Class A ordinary share and one-half of one redeemable
warrant. Each whole warrant will entitle the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject
to adjustment. Each warrant will become exercisable 30 days after the completion of the initial Business Combination and will expire
five years after the completion of the initial Business Combination, or earlier upon redemption or liquidation.

Warrants —No
warrants are currently outstanding. Each whole warrant entitles the holder to purchase one Class A ordinary share at a price of
$11.50 per share, subject to adjustment as discussed herein. The warrants cannot be exercised until 30 days after the completion
of the initial Business Combination, and will expire